Immune Checkpoint Inhibitors and Pre-existing Autoimmune Diseases
NCT ID: NCT03140137
Last Updated: 2019-04-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
112 participants
OBSERVATIONAL
2017-01-21
2018-01-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Patient-Reported AutoImmunity Secondary to Cancer immunothErapy
NCT03849131
Checkpoint Inhibitors in Patients With Cancer and Underlying Autoimmune Disease
NCT04805099
Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoint Inhibitors (ICPI) Treatment
NCT05813418
Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse
NCT03229382
Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy
NCT03595813
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Checkpoint inhibitor therapy
Treatment by ipilimumab, nivolumab or pembrolizumab for advanced cancer in clinical practice
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Immune checkpoint inhibitor therapy for an advanced cancer
Exclusion Criteria
* Absence of follow-up
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Brest
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Divi CORNEC
Role: STUDY_DIRECTOR
CHRU de Brest
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CH d'AIX
Aix-en-Provence, , France
CHU de DIJON
Dijon, , France
CHD Vendée
La Roche-sur-Yon, , France
Ch Le Mans
Le Mans, , France
CH de MACON
Mâcon, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHECKAUTO
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.